Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Fig. 4

a, c, e, g Survival rates of J82, T24, 5637 and KU-19-19 cells treated with Olaparib, at the indicated doses, in presence or absence of P5091 [1.5 μM] and RRx-001 [1.25 μM], for 144 h. The sensitivity to the Olaparib, in presence or absence of P5091 [1.5 μM] and RRx-001 [1.25 μM], was determined by the modified MTT assay (MTS), Cell Titer 96 AQueous One Solution assay, and expressed as IC50, ie 50% of the inhibitory concentration. The values are expressed as mean ± the standard deviation. b, d, f, h Isobologram analysis show the synergistic antiproliferative activity of RRx-001 plus P5091 plus Olaparib (starting from the Olaparib concentration of [2 μM]). In the upper panels, the graphs derived from the values given in the tables (lower panels) are shown. In the graphs the black dots below the dotted line indicate the presence of synergistic interaction between the two drugs. In the tables the Fractional Effect represents a percentage expression of the number of live cells. Values of CI < 1, CI = 1 and CI > 1 indicate respectively synergistic, additive and antagonistic effects

Back to article page